Philips showcases MR research solutions designed to enable collaboration with partners at the ISMRM Annual Meeting
- Open access to Philips imaging technologies allows researchers to develop advanced MR solutions to expand access to more patients
ANDOVER, Massachusetts, June 1, 2015 /PRNewswire/ -- Royal Philips (NYSE: PHG, AEX: PHIA) today announced the range of its Magnetic Resonance (MR) solutions to be showcased at the International Society for Magnetic Resonance in Medicine's (ISMRM) 23rd Annual Meeting & Exhibition in Toronto, Canada. Visitors to Philips booth #301 will see the latest in innovations designed in collaboration with clinicians and partners, to increase clinical performance, enhance patient experience and provide economic value. The solutions highlight Philips' commitment to making MR more accessible to patients, while improving diagnostic confidence.
Logo - http://photos.prnewswire.com/prnh/20140122/NE50581LOGO
"MR brings the best of cutting edge technologies and clinical applications in a robust way to address real world clinical challenges and disease states for people around the globe in multiple care settings across the health continuum," said Vinay Parthan, VP Research and Development MRI, Philips. "MR is also a nascent imaging modality and has tremendous scope for research and exploration. Philips is excited to collaborate with our research partners as we co-innovate to enhance patient care through intuitive and quantitative MR."
With acquisition, reconstruction and post processing research tools like Paradise Pulse Programming environment and Recon 2.0, Philips provides research partners access to key algorithms within its MR systems, allowing them to develop their own applications on Philips platforms.
"Our group has had a longstanding collaboration with Philips. A significant contributor to the success of this collaboration has been the ability to access their MR software source code, which has allowed us to delve deep into the system and create new imaging techniques to help with stroke research." said Dr. Chun Yuan, Ph.D., Professor in Radiology and Bioengineering, University of Washington, Seattle, U.S.A., and Professor and Director of Center for Biomedical Imaging Research, Tsinghua University, Beijing, China. "Ultimately, we believe this will help us to create new clinical methods to diagnose and treat patients at risk of having stroke before it happens."
The Philips ISMRM Booth #301 will feature the following research-only technologies:
- Philips Recon 2.0* – Flexible, high-end MR image reconstruction framework
- IntelliSpace Discovery* – Multi-modality visualization and analysis solution to facilitate research
The booth will also feature the following solution:
- Ingenia MR-RT MR-only simulation** – New approach in therapy that helps clinicians rely on MR as a primary imaging modality for prostate cancer treatment.
And the following commercially available product:
- Ingenia 3.0T CX – Designed to help you to explore new clinical fields with confidence, perform advanced clinical imaging to supports referrals and conduct routine imaging efficiently
For more information on Philips' presence at ISMRM, stop by the Philips booth #301, visit www.philips.com/ISMRM and follow the conversation on @PhilipsHealth.
For further information, please contact:
Kathy O'Reilly
Philips Group Communications
(mobile) +1-978-221-8919
[email protected]
Twitter: @kathyoreilly
About Royal Philips:
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people's lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2014 sales of EUR 21.4 billion and employs approximately 108,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at www.philips.com/newscenter.
* Device marketed for research applications only. Not for clinical use. Not available for sale in Canada
** Pending 510(k).Not available for sale in the U.S.A. Not available for sale in Canada.
Share this article